Business Description
Mira Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4145 | |||||
| Equity-to-Asset | 0.84 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | 6.23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.36 | |||||
| 9-Day RSI | 59.4 | |||||
| 14-Day RSI | 55.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.11 | |||||
| Quick Ratio | 6.11 | |||||
| Cash Ratio | 5.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 3.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -262.14 | |||||
| ROA % | -224.42 | |||||
| ROIC % | -1302.32 | |||||
| ROC (Joel Greenblatt) % | -13709.52 | |||||
| ROCE % | -201.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.5 | |||||
| Price-to-Tangible-Book | 6.41 | |||||
| EV-to-EBIT | -2.33 | |||||
| EV-to-EBITDA | -2.33 | |||||
| EV-to-FCF | -4.21 | |||||
| Price-to-Net-Current-Asset-Value | 6.41 | |||||
| Price-to-Net-Cash | 6.71 | |||||
| Earnings Yield (Greenblatt) % | -42.92 | |||||
| FCF Yield % | -20.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mira Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.697 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 55.45 | ||
| 14-Day ATR (€) | 0.091579 | ||
| 20-Day SMA (€) | 1.37 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.494 - 4.2 | ||
| Shares Outstanding (Mil) | 16.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mira Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mira Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mira Pharmaceuticals Inc Frequently Asked Questions
What is Mira Pharmaceuticals Inc(STU:K6S)'s stock price today?
The current price of STU:K6S is €1.41. The 52 week high of STU:K6S is €4.20 and 52 week low is €0.49.
When is next earnings date of Mira Pharmaceuticals Inc(STU:K6S)?
The next earnings date of Mira Pharmaceuticals Inc(STU:K6S) is 2025-02-12 Est..
Does Mira Pharmaceuticals Inc(STU:K6S) pay dividends? If so, how much?
Mira Pharmaceuticals Inc(STU:K6S) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers